NMPA Approves 63 Generic Drug Products (100 Specifications) via Consistency Evaluation, Featuring Chenxin Pharma, Kelun Pharma, and Qilu Pharma

Dec 23, 2025 20:30 CST Updated 20:30

Qilu Pharmaceutical

Specialty Formulations and Active Pharmaceutical Ingredients (API) Developer

Note: This article does not constitute any investment opinions or recommendations; please refer to official/company announcements for accuracy. This article only provides an introduction to medical and health-related drugs, not a recommendation of treatment plans (if involved), and does not represent the platform's position. Authorization is required for the reprint of any article.

According to the NMPA official website, the drug approval certificate delivery information released on December 23, 2025,63Species(100 Specifications)Passed/Deemed to have passed the consistency evaluation, involvingCisen Pharmaceutical、Sichuan Kelun Pharmaceutical、Qilu Pharmaceuticaland other pharmaceutical companies.

Screenshot source: NMPA

In this approval, from the perspective of the varieties that have passed the evaluation,Vonoprazan Fumarate Tablets,Calcium Folinate Injection,Trazodone Hydrochloride TabletsAll 3 varieties have welcomed 3Chinese pharmaceutical companies passed the evaluation on the same day.In addition，Amisulpride Oral Solution、Bisoprolol Amlodipine Tablets,Bumetanide Injection,Brexpiprazole Tablets,Ferrous Succinate Tablets,Oseltamivir Phosphate for Suspension,Calcium Chloride Injection7 VarietiesTwo pharmaceutical companies both received approval on the same day.According to the database of Mosepharm,Ferrous Succinate TabletsExceeding 440 million yuan in sales revenue in the Chinese hospital market in 2024.

Screenshot source: All-terminal Hospital Sales Database(Check data. Find Moentropy)

In this evaluation of dosage forms, tablets accounted for the highest proportion, reaching 39.4%, followed by injections, accounting for 35.5%. Regarding the first approvals, this time there areFinasteride and Tadalafil Capsules,Sodium Bicarbonate Hemofiltration Replacement Fluid,Lomefloxacin Hydrochloride Eye DropsFive varieties in total. For more detailed information, see the table and mini-program below.

List of Approved Varieties as of December 22, 2025 (First Approval Marked in Red)

To get the latest updates on approved products, click the mini-program to view in real time.

END

This article is original. Please leave a message to obtain authorization for reprint.

Recent Popular Resource Acquisition

Trends in Clinical Trials in China and the Outlook for International Multicenter Clinical Trials - 202505
2024 Pharmaceutical Enterprise Comprehensive Strength Ranking - 202505
Analysis Report on China's Herpes Zoster Vaccine Industry - 202505
2023H2-2024H1 Analysis Report on Pharmaceuticals in China - 202504
Data Perspective: Application, Approval, and Sales of Innovative Traditional Chinese Medicine, Classic Prescriptions, Improved New Drugs, and Same-name Same-formula Products - 202503
2024 China Class 1 New Drug Targets White Paper - 202503
Top 100 List of Innovative Development of AI Healthcare Enterprises in China - 202502
Decoding Skincare Anti-Aging: Consumer Preference Insights and Market Landscape Analysis - 202502
Analysis Report on New Drugs Approved by the FDA in 2024 - January 2025
Small Molecule Drug White Paper (I) - 202501
2024 China Healthcare Investment and Financing Panorama Insights Report - 202501
2024 Medical Insurance Negotiation and Market Analysis Report - 202501
More RecentlyMoxie ConsultingPopular Report, Scan the QR Code Below to Claim

Contact us to experience more professional services from MoEntropy Pharmaceutical.

WillDiscussion

CombinedWork

GardenDistrict

TakeService

Database

Consultation

Customization

Service

Media

Cooperation

ClickImage Above, you can start the MosEntropy chemical data query.

ClickReadRead the Original Text, apply for a free trial of Mosentropy Pharmaceutical Enterprise Edition!